Drug alert for Amoxil and Augmentin
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 4 drug alert for specified batches of Amoxil (amoxicillin trihydrate; GlaxoSmithKline) vials for injection 500mg and 1g, and Augmentin (co-amoxiclav; GlaxoSmithKline) intravenous 600mg and 1.2g. This is due to a very low incidence of cracks being found in vials used for packaging of the affected products. The cracks are positioned where the base of the vial meets the side wall and there are concerns that sterility may be breached in affected vials. Further information is available from the MHRA website.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066852
Recommended from Pharmaceutical Press
Pharmaceutics: Drug Delivery and Targeting systematically reviews important concepts for drug delivery systems and targeting of drugs.£24.00Buy now
All you need to know about prescribing or administering drugs via enteral feeding tubes. Over 400 drug monographs as well as facts to inform clinical decision making.£52.00Buy now
Remington Education: Drug Information & Literature Evaluation teaches students how to effectively and efficiently locate and analyze up-to-date drug information and literature.£26.00Buy now